The Market Reports

Synopsis

The global market for Viral Vectors and Plasmid DNA Manufacturing was estimated to be worth US$ 668 million in 2024 and is forecast to a readjusted size of US$ 4511 million by 2031 with a CAGR of 31.8% during the forecast period 2025-2031.

Viral vectors and plasmid DNA manufacturing represent essential infrastructure in the gene and cell therapy value chain, enabling the delivery and expression of therapeutic genes. Viral vectors—including AAV, adenovirus, and lentivirus—are foundational to CAR-T therapies, gene editing platforms, and vaccine development due to their efficient gene transfer capabilities.

Plasmid DNA, as a crucial upstream component, supports viral vector production, mRNA synthesis, and DNA vaccine development. As gene and cell therapies move toward large-scale commercialization, GMP-grade manufacturing capacity of viral vectors and plasmid DNA has become a strategic focal point for biopharma companies, CDMO platforms, and global investors.

As gene and cell therapies gain global regulatory approvals, demand for industrial-scale manufacturing of viral vectors and plasmid DNA is rapidly expanding. Blockbuster CAR-T products, AAV gene therapies, and mRNA vaccines continue to scale up, fueling the need for GMP-compliant platforms, robust quality systems, and high-purity raw materials. CDMO players are becoming the core force in industrial upgrading under the “asset-light” strategies of pharmaceutical companies. Governments worldwide are also promoting bio-manufacturing capacity through strategic funding, infrastructure support, and policy initiatives aimed at localization, modularity, and automation.

The industry faces significant technical and operational barriers, including high production costs, lack of standardized processes, and stringent quality control challenges. Key bottlenecks persist in high-purity plasmid preparation and efficient viral vector production, particularly in impurity removal and yield optimization. Regulatory frameworks are evolving rapidly across different regions, requiring manufacturers to navigate diverse GMP compliance requirements and stricter approval thresholds. Additionally, the high concentration of capacity among top-tier CDMOs intensifies competition and pricing pressure, raising the market entry threshold for emerging players.

The downstream market is transitioning from academic labs and early-stage biotech firms to commercial-stage biopharmaceutical companies, with order volumes scaling from grams to kilograms. AAV, LNP-mRNA, and CAR-T pipelines heavily rely on customized viral vectors and high-quality plasmids. In rare diseases, oncology, and vaccine development, demand is rising for delivery tools with enhanced expression, reduced immunogenicity, and controlled safety. This is driving the construction of scalable, modular GMP manufacturing systems that can meet precise, application-specific requirements.

This report aims to provide a comprehensive presentation of the global market for Viral Vectors and Plasmid DNA Manufacturing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Viral Vectors and Plasmid DNA Manufacturing by region & country, by Type, and by Application.

The Viral Vectors and Plasmid DNA Manufacturing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors and Plasmid DNA Manufacturing.

Market Segmentation

By Company

• Thermo Fisher Scientific
• Lonza
• Azenta Life Sciences
• Revvity
• VectorBuilder
• Takara Bio
• GenScript Biotech
• Gene Chem
• Geno Meditech
• PackGene Biotech
• VIROVEK
• OriGen
• Vector BioLabs

Segment by Type

• AAV
• Lentiviruses
• Retroviruses
• Adenoviruses
• DNA Plasmids
• Other

Segment by Application

• Pharmaceutical and Biopharmaceutical Companies
• Academics and Research Institutes

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.